36 is the new 18: Functional high-risk multiple myeloma in the modern era.
Where this comes from
- Record sourced from PubMed, PMID 42495845.
- Also identified by DOI 10.1002/cncr.70548 and PMC identifier 13397403.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of <i>Cancer</i>, a threshold of 36 months (rather than 18 months) is established as the optimal threshold for the identification of functional high‐risk multiple myeloma. Early use of T‐cell–redirection therapies may improve outcomes for these patients.